

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM501039

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
OCUNEXUS THERAPEUTICS, INC.		10/01/2018	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	EYEVANCE PHARMACEUTICALS LLC		
Street Address:	777 Taylor Street, Suite 1050		
City:	Ft. Worth		
State/Country:	TEXAS		
Postal Code:	76102		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	78602587	NEXAGON	
CORRESPONDENCE DATA			
Fax Number:	6197442201		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	6197442200		
Email:	idocketing@duanemorris.com		
Correspondent Name:	DUANE MORRIS LLP		
Address Line 1:	750 B Street, Suite 2900		
Address Line 4:	SAN DIEGO, CALIFORNIA 92101-4681		
NAME OF SUBMITTER:	Vicki G. Norton		
SIGNATURE:	/Vicki G. Norton/		
DATE SIGNED:	12/06/2018		
Total Attachments: 4			
source=EXECUTED_Eyevance-Ocunexus_Trademark_Assignment#page1.tif			
source=EXECUTED_Eyevance-Ocunexus_Trademark_Assignment#page2.tif			
source=EXECUTED_Eyevance-Ocunexus_Trademark_Assignment#page3.tif			
source=EXECUTED_Eyevance-Ocunexus_Trademark_Assignment#page4.tif			

CH \$40.00 78602587

TRADEMARK ASSIGNMENT

This **Trademark Assignment** (“**Trademark Assignment**”) is made and entered into as of October 1, 2018, by and between **Ocunexus Therapeutics, Inc.**, a Delaware corporation having its principal address at 12481 High Bluff Drive #150, San Diego, CA 92130 (“**Assignor**”), and **Eyevance Pharmaceuticals LLC**, a Delaware limited liability company having its principal address at 777 Taylor Street, Suite 1050, Ft. Worth, Texas 76102 (“**Assignee**” and, together with **Assignor**, the “**Parties**” and each, a “**Party**”).

RECITALS

WHEREAS, Assignor and Assignee have entered into a certain License and Collaboration Agreement dated September 18, 2018 (the “**Agreement**”); and

WHEREAS, pursuant to the Agreement, Assignor has agreed to, among other things, sell, assign, transfer, convey and deliver to Assignee its entire right, title and interest in, to and under the trademarks (the “**Marks**”) set forth on the attached **Schedule 1**, together with the goodwill associated therewith.

ASSIGNMENT

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby sells, assigns, transfers, conveys and delivers to Assignee and its successors and assigns, Assignor’s entire right, title and interest in and to the Marks set forth on **Schedule 1**, together with the goodwill associated therewith, and any and all accounts, contract rights, warranties, litigation claims and rights, including the right to sue for and collect upon all claims for profits and damages as a result of past infringement, if any, and other general intangibles of Assignor related to any of the Marks.

Assignor further agrees that it shall on the date hereof and from time to time thereafter, at the request and expense of Assignee, perform or cause to be performed such acts and execute, acknowledge and deliver at the request of Assignee, such documents as may reasonably be required to evidence or effectuate the sale, conveyance, assignment, transfer and delivery to Assignee of the Marks or for the performance by Assignor of any of its obligations hereunder.

[Signature page follows]


IN WITNESS WHEREOF, the Parties have caused this Trademark Assignment to be duly executed on their respective behalf, by their respective officers thereunto duly authorized, all as of the day and year first above written.

ASSIGNOR

ASSIGNEE

Ocunexus Therapeutics, Inc.

Eyevance Pharmaceuticals LLC

By: 

By: _____

Name: David Pool

Name: _____

Title: CFO

Title: _____

[Signature Page to Trademark Assignment]

IN WITNESS WHEREOF, the Parties have caused this Trademark Assignment to be duly executed on their respective behalf, by their respective officers thereunto duly authorized, all as of the day and year first above written.

ASSIGNOR

Ocunexus Therapeutics, Inc.

By: _____

Name: _____

Title: _____

ASSIGNEE

Eyevance Pharmaceuticals LLC

By: Jerry St. Peter

Name: Jerry St. Peter

Title: CEO

[Signature Page to Trademark Assignment]

SCHEDULE 1

1. US Marks

Trademark	Country	Serial No.	Filing Date	Reg. No.	Reg. Date
NEXAGON	US	78602587	4/5/2005	3490217	8/19/2008